At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Fluocinolone Acetonide/Medidur +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Masked, Randomized Comparison of the Safety and Efficacy of 0.2 and 0.5 µg/Day Fluocinolone Acetonide/Medidur™ in Patients With Exudative Age Related Macular Degeneration Who Have Received Lucentis™
In Brief
A Phase 2 clinical trial evaluating Fluocinolone Acetonide/Medidur for Age Related Macular Degeneration. Completed, enrolled 6 participants across 1 site.
Detailed Summary
Treatment of exudative age-related macular degeneration has been significantly improved by the advent of Lucentis™( which provides improved vision rather than simply stabilization) is common; however, monthly injections may be required to maintain this effect. It is hypothesized that sustained release fluocinolone acetonide will allow maintenance of the improved vision with fewer Lucentis injections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge Related Macular Degeneration
CountriesUnited States
CollaboratorsAlimera Sciences, pSiVida Limited
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2008
Primary CompletionNov 2011
TodayJul 2026
First PostedJan 31, 2008
Enrollment StartJan 1, 2008
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.4 years ago
Interventions
Fluocinolone Acetonide/Medidurdrug
0.2 ug/day implant
Fluocinolone Acetonide/Medidurdrug
0.5 ug/day implant